PHAXIAM Therapeutics S.A. (PHXM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has a cash flow conversion efficiency ratio of -0.540x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-8.34 Million ≈ $-9.75 Million USD) by net assets (€15.45 Million ≈ $18.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of PHAXIAM Therapeutics S.A. to measure how many days the company can operate on defensive assets alone.
PHAXIAM Therapeutics S.A. - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how PHAXIAM Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
PHAXIAM Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Value & Income Trust
LSE:VIP
|
0.013x |
|
The Pebble Group PLC
LSE:PEBB
|
0.180x |
|
Audioboom Group plc
LSE:BOOM
|
0.076x |
|
Oasis Crescent Property Fund
JSE:OAS
|
-0.007x |
|
Ausmon Resources Ltd
AU:AOA
|
-0.232x |
|
BioNeutra Global Corp
V:BGA
|
-0.004x |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
-0.007x |
|
The Real Good Food Company, Inc.
NYSE:RGFC
|
N/A |
Annual Cash Flow Conversion Efficiency for PHAXIAM Therapeutics S.A. (2012–2023)
The table below shows the annual cash flow conversion efficiency of PHAXIAM Therapeutics S.A. from 2012 to 2023. For the full company profile with market capitalisation and key ratios, see PHXM company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €25.61 Million ≈ $29.94 Million |
€-24.43 Million ≈ $-28.56 Million |
-0.954x | +29.97% |
| 2022-12-31 | €23.49 Million ≈ $27.46 Million |
€-31.99 Million ≈ $-37.40 Million |
-1.362x | +45.55% |
| 2021-12-31 | €22.84 Million ≈ $26.71 Million |
€-57.14 Million ≈ $-66.81 Million |
-2.501x | -27.55% |
| 2020-12-31 | €26.54 Million ≈ $31.03 Million |
€-52.05 Million ≈ $-60.85 Million |
-1.961x | -285.69% |
| 2019-12-31 | €85.56 Million ≈ $100.03 Million |
€-43.51 Million ≈ $-50.86 Million |
-0.508x | -88.53% |
| 2018-12-31 | €145.60 Million ≈ $170.22 Million |
€-39.27 Million ≈ $-45.91 Million |
-0.270x | -98.08% |
| 2017-12-31 | €181.42 Million ≈ $212.10 Million |
€-24.70 Million ≈ $-28.88 Million |
-0.136x | +72.50% |
| 2016-12-31 | €35.64 Million ≈ $41.66 Million |
€-17.64 Million ≈ $-20.63 Million |
-0.495x | -60.07% |
| 2015-12-31 | €47.13 Million ≈ $55.10 Million |
€-14.58 Million ≈ $-17.04 Million |
-0.309x | -53.08% |
| 2014-12-31 | €35.82 Million ≈ $41.88 Million |
€-7.24 Million ≈ $-8.46 Million |
-0.202x | +57.59% |
| 2013-12-31 | €13.59 Million ≈ $15.88 Million |
€-6.47 Million ≈ $-7.57 Million |
-0.476x | -208.76% |
| 2012-12-31 | €-4.03 Million ≈ $-4.71 Million |
€621.40K ≈ $726.48K |
-0.154x | -- |
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more